Go to Content Go to Navigation Go to Navigation Go to Site Search Homepage

Opill’s FDA Approval Is a Win for Repro & Sexual Health Care

By Colt Wasserman, MD

This summer, after nearly 20 years of work by reproductive justice advocates, the Food and Drug Administration (FDA) approved the first over-the-counter (OTC) birth control pill in the United States. Opill, AKA norgestrel 0.075 mg, is a progestin-only oral contraceptive that can be safely used by sexually active people to prevent pregnancy.

This is great news!

It’s a victory after a year of steadily increasing attacks on reproductive rights and bodily autonomy. It’s in sync with public opinion, given that 9 in 10 adults believe everyone deserves access to the full range of contraception options and over 70 percent of adults in the U.S. support making birth control pills available over the counter. It’s completely safe, as confirmed by leading medical associations such as the American College of Obstetricians and Gynecologists, the American Medical Association, and the American Academy of Family Physicians.

And, not least of all, a birth control pill that doesn’t require a prescription is a win for patients seeking reproductive and sexual health care – especially those from historically marginalized communities, including Black and Indigenous folx, people living with disabilities, LGBTQ+ folx, immigrants, people struggling to make ends meet, and young people. The FDA’s decision has removed a major barrier to accessing oral contraception: Folx will no longer need to book a doctor’s appointment in order to start taking the birth control pill, and they can avoid all the related obstacles (getting time off for the appointment, finding childcare, finding transportation, etc.). Opill empowers patients to make their own reproductive decisions, on their own time, and at their own convenience.

To be clear, increased access to birth control is not a solution to the ongoing assault on abortion access and sexual and reproductive health care. But it is critical to protecting our reproductive freedom. As we celebrate the approval of Opill alongside the Free the Pill Coalition, who has led this movement, Planned Parenthood of Central and Western New York will continue to work with our partners to advocate for the removal of economic, political, and social barriers to care.

Planned Parenthood cares about your data privacy. We and our third-party vendors use cookies and other tools to collect, store, monitor, and analyze information about your interaction with our site to improve performance, analyze your use of our sites and assist in our marketing efforts. You may opt out of the use of these cookies and other tools at any time by visiting Cookie Settings. By clicking “Allow All Cookies” you consent to our collection and use of such data, and our Terms of Use. For more information, see our Privacy Notice.

Cookie Settings

Planned Parenthood cares about your data privacy. We and our third-party vendors, use cookies, pixels, and other tracking technologies to collect, store, monitor, and process certain information about you when you access and use our services, read our emails, or otherwise engage with us. The information collected might relate to you, your preferences, or your device. We use that information to make the site work, analyze performance and traffic on our website, to provide a more personalized web experience, and assist in our marketing efforts. We also share information with our social media, advertising, and analytics partners. You can change your default settings according to your preference. You cannot opt-out of required cookies when utilizing our site; this includes necessary cookies that help our site to function (such as remembering your cookie preference settings). For more information, please see our Privacy Notice.

Marketing

On

We use online advertising to promote our mission and help constituents find our services. Marketing pixels help us measure the success of our campaigns.

Performance

On

We use qualitative data to learn about your user experience and improve our products and services.